L-Palmitoylcarnitine TFA
产品介绍 | L-PalmitoylcarnitineTFA 是一种长链酰基肉碱和脂肪酸代谢产物,在缺血期间积聚于肌膜并扰乱膜脂环境。L-Palmitoylcarnitine TFA 通过与 Kir6.2 的相互作用抑制 KATP 通道活性,而不影响单通道电导。 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
生物活性 | L-Palmitoylcarnitine TFA, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine TFA inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2. | ||||||||||||||||
体外研究 |
L-Palmitoylcarnitine (1 µM) inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2. L-Palmitoylcarnitine simultaneously enhances the ATP sensitivity of the channel (IC50 fell from 62 to 30 µM). 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
体内研究 | |||||||||||||||||
体内研究 | |||||||||||||||||
性状 | Solid | ||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 100 mg/mL (194.69 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||
参考文献 |